MaMa: Assessment of Motor Development With a Wearable in Rural and Low-income Settings

Sponsor
Helsinki University Central Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05782673
Collaborator
Tampere University (Other), University of Helsinki (Other), Kamuzu University of Health Sciences (Other)
100
4
33.6
25
0.7

Study Details

Study Description

Brief Summary

The MaMa study aims to assess feasibility and validity of an infant wearable in a rural settings. Altogether N~100 infants will be recruited and measured multiple times at homes from age 6 months to age 18 months. Neurodevelopment of the infants is assessed at 18-24 months of age to compare motor development trajectories with the later neurodevelopmental outcome.

Condition or Disease Intervention/Treatment Phase
  • Device: wearable MAIJU for motor assessment

Detailed Description

The MaMa study aims to assess the feasibility and validity of an infant wearable method to study young infants' neuromotor development in a low income setting. In this method, infants' motor abilities (e.g. variety of different postures and movement types) are measured using a playsuit equipped with movement sensors while the infant is freely playing in his/her native environment, such as home. The data recorded with the wearable sensors is analysed afterwards using an algorithm that quantifies individual movement and posture components as well as delivers holistic interpretations of infant's motor maturity. This method is developed in University of Helsinki, and it is already successfully used in clinical research projects in Finland, Denmark, Italy and USA. Use of movement sensors is common in other wellness and health applications, however wearables of this kind have not been used before for infant's neuromotor assessment. The solution has the advantage that it provides a fully objective and quantified representation of infant's motor activity in his/her native environment; which is not achievable with any of the currently used clinical assessment methods that are typically performed in the outpatient clinic environment.

The study will be conducted in rural Malawi, is East Africa. The investigators will assess the feasibility of the wearable method in a resource poor setting by running a pilot study on approximately five-to-seven-month-old infants. In the first phase, the investigators will assess technical suitability of wearable methods in 20 typically developing infants in the rural settings, and compare the results to those obtained from infants of the same age in Finland. In the second phase, the study will continue as a longitudinal follow-up of these infants and recruit a larger study group of Malawian infants (up to a total N~100), all of whom will undergo repeated assessment with the wearable method, every 6 weeks until the age of 18 months, or until they walk fluently. The results will support constructing motor growth charts for the Malawian infant population. At the age of 24 months, children's neuropsychological performance will be assessed using an assessment battery that was recently adapted for Malawian context; this will allow us to study how early motor development associates with later neurocognitive developmental profile.

There are three potential benefits from performing the study. First, to establish the practical feasibility and utility of a novel method for out-of-hospital neurological assessment in infants. Second, the project will establish functional motor growth charts for Malawian population to serve as a benchmark in any future intervention trial in comparable environments; these can be also compared to data from Finland. Finally, the project will allow assessing links between early motor and later cognitive development, a question with significant global health implications in all cultures.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Assessment of Motor Development With a Wearable in Rural and Low-income Settings: Feasibility and Validity of MAIJU Jumpsuit in Malawi
Anticipated Study Start Date :
Mar 15, 2023
Anticipated Primary Completion Date :
Mar 30, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Outcome Measures

Primary Outcome Measures

  1. Motor maturation level (BIMS) [The primary outcome BIMS is the level reached by 18 months of age]

    BIMS (Baba Infant Motility Score) is a score that combines all recorded postures and movement activities to a holistic estimate of infant's motor maturation. BIMS has a scale from 0 to 100, with higher number being better.

Secondary Outcome Measures

  1. Kilifi Developmental Inventory (KDI) score [24 months of age]

    KDI is a questionnaire based assessment of infants' neurocognitive development at 12-24 months of age. It is validated in the Malawi context. The scale is 0-70, with higher number being better.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Months to 24 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • A documented birth date

  • Birth at about term age, i.e. between 35 and 42 gestation weeks

  • Mother's ability to speak fluently Chi-Chewa, Chi-Yao or English

  • Permanent resident of Lungwena Health Centre catchment area

  • Availability and willingness of the mother and infant during the period of the study

  • Signed or thumb-printed informed consent by the caregiver of the infant

Exclusion Criteria:
  • Very early birth (at 7th month or earlier) based on mother's information

  • Infant's congenital malformation or severe illness as judged clinically by a study nurse

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Helsinki Helsinki Finland 00250
2 BABA, Clinical Trial Unit, New Children's Hospital Helsinki Finland
3 Lungwena Health Center Mangochi Mangochi District Malawi
4 Kamuzu University of Health Sciences Blantyre Malawi 3

Sponsors and Collaborators

  • Helsinki University Central Hospital
  • Tampere University
  • University of Helsinki
  • Kamuzu University of Health Sciences

Investigators

  • Principal Investigator: Sampsa Vanhatalo, MD PhD, professor in physiology, consultant in clinical neurophysiology

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Sampsa Vanhatalo, professor in physiology, consultant in clinical neurophysiology, Helsinki University Central Hospital
ClinicalTrials.gov Identifier:
NCT05782673
Other Study ID Numbers:
  • MaMa2022
First Posted:
Mar 23, 2023
Last Update Posted:
Mar 27, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sampsa Vanhatalo, professor in physiology, consultant in clinical neurophysiology, Helsinki University Central Hospital

Study Results

No Results Posted as of Mar 27, 2023